Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Rhea-AI Summary

Quince Therapeutics (Nasdaq: QNCX) has announced an upcoming investor webinar focused on Ataxia-Telangiectasia (A-T), scheduled for February 7, 2025, at 10:00 a.m. Eastern Time. The webinar will feature Dr. Mary Kay Koenig, a leading A-T expert and board-certified child neurologist, who will present on A-T natural history, current treatments, competitive landscape, and Quince's Phase 3 EryDex clinical trial.

Dr. Dirk Thye, Quince's CEO and CMO, will provide a corporate overview and update on the ongoing Phase 3 NEAT clinical trial enrollment. Dr. Koenig, currently serving as Professor and Associate Vice-Chair for Clinical Research at McGovern Medical School, brings extensive expertise in neurodegenerative disorders and holds multiple leadership positions, including Director at the Center for Treatment of Pediatric Neurodegenerative Disease.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it will host an investor webinar focused on addressing the high unmet need in the company’s lead rare pediatric neurodegenerative disease indication, Ataxia-Telangiectasia (A-T). The virtual webinar event will take place on Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time.

The webinar will feature leading A-T key opinion leader (KOL) Mary Kay Koenig, M.D., who will: 1) provide an A-T natural history overview, 2) detail current symptomatic treatment approaches for patients with A-T, 3) discuss the competitive therapeutic A-T landscape, and 4) provide an overview of Quince’s Phase 3 clinical trial of EryDex for the treatment of A-T. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will join the discussion to provide a corporate and scientific overview, as well as an enrollment update on the company’s ongoing Phase 3 NEAT clinical trial.

Mary Kay Koenig, M.D., is a board certified child neurologist specializing in neurodegenerative disorders, including A-T, mitochondrial disease, and tuberous sclerosis complex. She currently serves as a Professor and Associate Vice-Chair for Clinical Research in the Department of Pediatrics, Division of Child and Adolescent Neurology at the McGovern Medical School at the University of Texas, Houston. Dr. Koenig is also an Endowed Chair of Mitochondrial Medicine at the McGovern Medical School at the University of Texas, Houston, in addition to serving as a Director at the Center for the Treatment of Pediatric Neurodegenerative Disease and a Co-Director of the Tuberous Sclerosis Center within the UTHealth Houston system – one of the nation’s most comprehensive academic health science centers. She strives to provide excellent clinical care and advance research for children afflicted with genetic neurodegenerative disease. Dr. Koenig also works to mentor and educate junior faculty, fellows, residents, and medical students in the art of medicine and clinical research. She received her M.D. from St. George’s University School of Medicine and completed her pediatrics residency at the University of Texas Medical Branch in Galveston, Texas, in addition to a fellowship in child and adolescent neurology at the University of Texas Medical School in Houston, Texas.

To register for this webinar, please click here. A live webcast of the presentation will be accessible on Quince’s Events page under the News & Events heading of the company’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250128480561/en/

Media & Investor Contact:

Stacy Roughan

Quince Therapeutics, Inc.

Vice President, Corporate Communications & Investor Relations

ir@quincetx.com

Source: Quince Therapeutics, Inc.

FAQ

When is Quince Therapeutics (QNCX) hosting its A-T focused investor webinar?

Quince Therapeutics is hosting the investor webinar on Friday, February 7, 2025, at 10:00 a.m. Eastern Time.

What will be discussed in QNCX's February 2025 investor webinar?

The webinar will cover A-T natural history, current treatments, competitive landscape, and updates on Quince's Phase 3 EryDex clinical trial for A-T treatment, along with enrollment updates for the Phase 3 NEAT trial.

Who is the key opinion leader presenting at QNCX's A-T webinar?

Dr. Mary Kay Koenig, a board-certified child neurologist and Professor at McGovern Medical School, will be the key opinion leader presenting at the webinar.

What is the current stage of QNCX's EryDex treatment for Ataxia-Telangiectasia?

EryDex is currently in Phase 3 clinical trials for the treatment of Ataxia-Telangiectasia.

How can investors access QNCX's February 2025 A-T webinar?

Investors can register through the provided link and access the live webcast on Quince's Events page under the News & Events section of their Investor Relations website at ir.quincetx.com.